Skip to main content
    W

    Waters Corporation (WAT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $457.84
    +4.76 (+1.05%)

    Market Cap: $44.49B

    Last updated: Nov 06, 2026 at 4:21 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    93%(37/40)
    Avg Surprise
    +6.41%
    Streak
    14 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$5.26
    Range$5.14 - $5.34
    23 analysts
    Revenue Consensus
    $1.9B
    Range$1.9B - $1.9B
    22 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$5.26$5.14 - $5.34--23--
    Sep 26
    Reported Nov 3
    		$4.10$3.99$3.92 - $4.03+2.76%Beat20
    1
    0
    30d
    		+20.6%
    Jun 26
    Reported Aug 4
    		$3.05$3.01$2.98 - $3.04+1.33%Beat20
    2
    1
    30d
    		+3.4%
    Mar 26
    Reported May 5
    		$2.70$2.31$2.27 - $2.35+16.88%Beat18
    4
    4
    30d
    		+20.0%
    Dec 25
    Reported Feb 9
    		$4.53$4.51$4.45 - $4.55+0.44%Beat17
    1
    1
    30d
    		+10.5%
    Sep 25
    Reported Nov 4
    		$3.40$3.22$3.17 - $3.23+5.59%Beat12
    1
    1
    30d
    		+16.0%
    Jun 25
    Reported Aug 4
    		$2.95$2.94$2.88 - $3.10+0.34%Beat15
    3
    0
    30d
    		+12.2%
    Mar 25
    Reported May 6
    		$2.25$2.22$2.17 - $2.26+1.35%Beat18
    3
    2
    30d
    		+1.8%
    Dec 24
    Reported Feb 12
    		$4.10$4.03$3.99 - $4.10+1.74%Beat18
    1
    0
    30d
    		+13.3%
    Sep 24
    Reported Nov 1
    		$2.93$2.68$2.64 - $2.73+9.33%Beat18
    2
    0
    30d
    		+3.2%
    Jun 24
    Reported Jul 31
    		$2.63$2.56$2.50 - $2.60+2.73%Beat17
    1
    0
    30d
    		-6.1%
    Mar 24
    Reported May 7
    		$2.21$2.09$2.05 - $2.14+5.74%Beat16
    4
    0
    30d
    		-11.2%
    Dec 23
    Reported Feb 6
    		$3.62$3.55$3.48 - $3.60+1.97%Beat17
    No revisions (30d)
    		-5.7%

    Key Metrics

    Valuation
    P/E Ratio31.84EV/EBITDA41.29x
    Price/FCF112.84xFCF Yield0.89%
    Profitability
    Profit Margin1.76%Operating Margin11.40%
    ROE1.12%ROIC1.33%
    Financial Health
    Debt/Equity0.33xInterest Coverage2.23x
    Current Ratio1.86xQuick Ratio1.29x
    Trading Statistics
    Beta1.15Avg Volume1.04M
    52-Week High$482.2852-Week Low$282.77

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$463.21
    SMA 20$452.75
    SMA 50$434.52
    SMA 200$371.14
    EMA 10$458.84
    EMA 20$453.51
    EMA 50$436.80
    EMA 200$389.93

    MACD

    Line: 8.03Signal: 9.25Hist: -1.22

    ADX

    ADX: 31.1+DI: 20.5-DI: 15.1

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down16.0
    PSAR$482.28

    Bollinger Bands

    Upper Band$481.89
    Lower Band$423.61
    %B Position1287%(Upper)
    Band Width0.59

    RSI (14-Day)

    Neutral
    54.2

    Momentum Oscillators

    Stoch %K58.1
    Stoch %D58.2
    Williams %R-45.0
    ROC (10d)0.9%
    Momentum4.17
    CCI (20d)29.5
    MFI (14d)65.4

    Volatility Measures

    ATR (14d)$15.52(3.4%)
    StdDev (20d)14.57
    Hist Vol31.5%(Moderate)

    Volume Flow

    VWAP$457.59
    OBV5.5M
    AD Line7.4M
    CMF (20d)-0.023

    Volume Metrics

    Avg Vol (20d)1.0M
    Vol Ratio0.7x
    VWMA (20d)$453.32

    Pivot Points

    R3$476.94
    R2$471.66
    R1$462.37
    Pivot Point$457.08
    S1$447.79
    S2$442.51
    S3$433.22

    Advanced Oscillators

    TSI17.04
    Ultimate Osc43.7
    KST76.62

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.65B$1.27B$932.36M$799.89M$771.00M$662.00M$872.71M$740.30M$708.53M$636.84M$819.47M$711.69M
    Cost of Revenue$911.00M$679.00M$362.86M$327.81M$321.00M$277.00M$348.52M$301.65M$288.24M$261.79M$318.36M$291.41M
    Gross Profit$734.00M$588.00M$569.50M$472.08M$450.00M$385.00M$524.20M$438.65M$420.29M$375.05M$501.11M$420.29M
    Operating Expenses$820.00M$635.00M$298.98M$279.97M$262.00M$233.00M$231.94M$227.52M$231.17M$241.21M$236.89M$240.86M
    R&D$122.00M$96.00M$46.90M$53.64M$49.00M$47.00M$46.91M$45.34M$46.18M$44.59M$44.39M$41.99M
    SG&A$405.00M$387.00M$240.01M$214.23M$198.00M$174.00M$173.27M$169.10M$173.25M$174.54M$180.36M$186.75M
    Operating Income$-86,000,000$-47,000,000$270.52M$192.11M$188.00M$152.00M$292.26M$211.13M$189.11M$133.85M$264.22M$179.43M
    Interest Income$5.00M$6.00M$5.67M$4.71M$5.00M$4.00M$4.56M$4.26M$4.33M$4.27M$4.64M$3.88M
    Interest Expense$60.00M$48.00M$14.29M$26.64M$15.00M$14.00M$19.00M$21.43M$23.73M$25.52M$30.70M$30.44M
    Income Before Tax$-141,000,000$-88,000,000$264.18M$170.12M$178.00M$143.00M$276.98M$193.62M$169.41M$114.86M$237.60M$153.19M
    Income Tax Expense$-5,000,000$-16,000,000$38.97M$21.20M$31.00M$22.00M$45.59M$32.11M$26.68M$12.66M$21.39M$18.64M
    Net Income$-136,000,000$-72,000,000$225.21M$148.92M$147.00M$121.00M$231.40M$161.50M$142.74M$102.20M$216.21M$134.55M
    EBITDA$468.00M$161.00M$325.34M$244.72M$238.00M$203.00M$340.00M$258.30M$236.04M$184.62M$311.73M$227.56M
    EBIT$-86,000,000$-46,000,000$272.80M$192.04M$187.00M$153.00M$291.42M$210.79M$188.81M$136.10M$263.67M$179.75M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about WAT

    News

    Waters Corporation Reports $1.77 Billion In Third Quarter 2026 Revenue And Raises Full-Year Guidance

    Waters Corporation announced third-quarter 2026 revenue of $1.77 billion, surpassing its guidance, driven by organic growth and contributions from acquired businesses. The company reported adjusted earnings per share...

    Pulse 2.0•11/6/26•Bullish

    Waters Acquires Chadds Ford’s MOBILion Systems to Expand Into Proteomics With High-Resolution Ion Mobility Technology

    Waters Corporation has acquired MOBILion Systems, a developer of SLIM high-resolution ion mobility separation technology...

    BioBuzz•11/6/26•Bullish

    Danaher (DHR) Won FDA Clearances, Is The Discount Too Cautious?

    Danaher (DHR) has gained renewed investor interest following recent FDA clearances for its Cepheid Xpert Hemorrhagic Fever Panel and Beckman Coulter Access MeMed BV assay...

    Simply Wall St•11/6/26•Neutral

    Becton, Dickinson and Company Q4 Earnings Call Highlights

    Becton, Dickinson and Company (BDX) reported higher fiscal fourth-quarter revenue and adjusted earnings, driven by demand for patient monitoring and biologic drug delivery products...

    TradingView•11/6/26•Neutral

    Waters Corporation Acquires MOBILion Systems To Expand Mass Spectrometry And AI-Powered Proteomics Capabilities

    Waters Corporation has acquired MOBILion Systems, a developer of high-resolution ion mobility separation technology...

    Pulse 2.0•11/6/26•Bullish

    WAT Valuation and Fair Value

    P/E
    31.8x
    Forward P/E
    27.5x
    EV/EBITDA
    41.3x
    P/FCF
    112.8x
    PEG
    1.7x
    P/B
    3.0x
    See GNG's fair value

    WAT Profitability: Margins, ROIC and FCF

    Gross margin
    50.9%
    Operating margin
    11.4%
    Net margin
    1.8%
    ROIC
    1.3%
    ROE
    1.1%
    FCF yield
    0.9%

    WAT Competitors

    CompanyTicker
    Agilent Technologies IncA
    BeOne Medicines AGONC
    Teva Pharma Industries Ltd ADRTEVA
    IQVIA Holdings IncIQV
    Humana IncHUM
    Haleon plcHLN
    Veeva Systems Inc Class AVEEV
    Royalty Pharma PlcRPRX

    Sector: Healthcare

    WAT Analyst Ratings

    Consensus
    Buy
    Analysts
    23
    Strong Buy
    3
    Buy
    15
    Hold
    4
    Sell
    0
    Strong Sell
    1

    WAT Bull Case vs Bear Case

    Bull case

    • WAT beat EPS estimates in 100.0% of its last 8 reported quarters.
    • WAT grew quarterly revenue 120.9% year over year.
    • 78.3% of WAT's analyst ratings are Buy or Strong Buy.

    WAT Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    3.8%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $5.26

    WAT Earnings Date

    WAT reports Feb 8, 2027, after the close. The date is confirmed.

    WAT Earnings Call

    The latest WAT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    WAT ETF Holders

    GNG tracks 36 ETFs that hold WAT. The largest weights:

    1. Invesco Water Resources ETF (PHO), 7.49% of the fund
    2. Invesco S&P 500 Equal Weight Health Care ETF (RSPH), 1.74% of the fund
    3. State Street Health Care Select Sector SPDR ETF (XLV), 0.69% of the fund
    4. iShares U.S. Healthcare ETF (IYH), 0.65% of the fund
    5. BlackRock Health Sciences Trust (BME), 0.61% of the fund
    Open the ETF Stock Exposure tool for WAT

    See insider activity

    Frequently Asked Questions About WAT

    When does WAT report earnings?

    Waters Corporation (WAT) is confirmed to report earnings on Feb 8, 2027.

    Does WAT pay dividends?

    Waters Corporation (WAT) does not currently pay a regular dividend.

    What is WAT's P/E ratio?

    Waters Corporation has a price-to-earnings (P/E) ratio of 31.84.

    What is WAT's market cap?

    Waters Corporation (WAT) has a market capitalization of $44.49B with a current stock price of $457.84.

    Related stocks

    Sector: Healthcare

    All stocks starting with W

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In